Skip to main
HOTH

Hoth Therapeutics (HOTH) Stock Forecast & Price Target

Hoth Therapeutics (HOTH) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Hoth Therapeutics is poised for success with its strong pipeline addressing unmet medical needs in the areas of cancer, skin toxicities, Alzheimer's, and obesity. The company is making significant progress in preclinical and clinical development, with key milestones such as IND submissions and potential partnerships on the horizon. However, investors should also be aware of potential risks, including regulatory and financial risks, when considering investment opportunities with Hoth Therapeutics.

Bears say

Hoth Therapeutics is currently focusing on developing multiple treatments for various medical needs such as cancer, mast-cell derived cancers and anaphylaxis, Alzheimer's, and obesity. However, despite positive data on its HT-001 drug, the lack of controlled clinical evidence and detailed efficacy information raises concern about the company's ability to successfully bring any of its treatments to market, especially with potential risks such as clinical/regulatory and financial challenges. Without clear validation, investors may find the stock too risky to invest in.

Hoth Therapeutics (HOTH) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hoth Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hoth Therapeutics (HOTH) Forecast

Analysts have given Hoth Therapeutics (HOTH) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Hoth Therapeutics (HOTH) has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hoth Therapeutics (HOTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.